PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Biochem Soc Trans. Author manuscript; available in PMC 2010 April 1.
Published in final edited form as:
PMCID: PMC2848482
NIHMSID: NIHMS188389

Impact of dietary amino acids and polyamines on intestinal carcinogenesis and chemoprevention in mouse models

Abstract

Colon cancer in humans is influenced by both genetic and dietary risk factors. The majority of colon cancers have somatic mutations in the APC (adenomatous polyposis coli) tumour-suppressor gene. Dietary arginine enhances the risk of APC-dependent colon carcinogenesis in mouse models by a mechanism involving NOS2 (nitric oxide synthase 2), as elimination of NOS2 alleles suppresses this phenotype. DFMO (difluoromethylornithine), a specific inhibitor of polyamine synthesis, also inhibits dietary arginine-induced colon carcinogenesis in C57BL/6J-ApcMin/J mice. The primary consequence of dietary arginine is to increase the adenoma grade in these mice. Either loss of NOS2 alleles or inhibition of polyamine synthesis suppresses the arginine-induced increase in adenoma grade. In addition to promoting intestinal carcinogenesis, polyamines can also reduce the efficacy of certain intestinal cancer chemopreventive agents. The NSAID (non-steroidal anti-inflammatory drug) sulindac is a potent inhibitor of intestinal carcinogenesis in the C57BL/6J-ApcMin/J mouse model and is used to treat humans with FAP (familial adenomatous polyposis). Dietary putrescine reduces the ability of sulindac to suppress intestinal tumorigenesis in the mouse model. These data suggest that reducing polyamine metabolism and dietary polyamine levels may enhance strategies for colon cancer chemoprevention.

Keywords: adenomatous polyposis coli (APC), arginine, cancer prevention, colon cancer, non-steroidal anti-inflammatory drug (NSAID), polyamine

Introduction

The rationale for interest in the ubiquitous polyamines in intestinal and colon carcinogenesis stems from experimental evidence in human cells and genetically altered mouse models indicating that the gene encoding ODC (ornithine decarboxylase), the first enzyme in polyamine synthesis, is regulated by the product of the APC (adenomatous polyposis coli) tumour-suppressor gene [1,2]. APC is a component of the Wnt signalling pathway, which is crucial for normal intestinal development, and is mutated in FAP (familial adenomatous polyposis), an inherited syndrome associated with increased risk of colon cancer in humans [3]. APC acts to regulate ODC gene expression via a mechanism involving the c-Myc oncogene protein product, which is reviewed elsewhere [4,5], as depicted in Figure 1. The majority of non-FAP colon cancers contain somatic mutations in the APC gene [6], indicating the relevance of this pathway in human colon carcinogenesis. Details of this pathway are further supported by evidence indicating that either conditional knockout of the c-myc gene in intestinal epithelial cells [7], or treatment with a specific ODC inhibitor [1], reduces intestinal tumorigenesis in the ApcMin/+ mouse model of FAP. As indicated in Figure 1, tissue polyamines are derived from metabolism via ODC and transport from extracellular sources. Polyamine metabolism is dependent on levels of the precursor amino acids arginine and ornithine, while transport in polarized colonic epithelial cells is dependent on two potentially unique sources of polyamines. The colonic lumen contains polyamines found in the diet or exported by enteric bacteria, and these polyamines are transported via mechanisms not yet well described on the apical surface [8,9]. Polyamines circulating in the blood can also find their way into colonic epithelial cells via basolateral transporters, which are also not well described to date. Arginine transport into colonic epithelial cells occurs presumably via basolateral transporters, as the major flux of this amino acid is from the intestines, in the fed state, or muscles to the liver and kidney, during starvation [10]. This mini-review focuses on recent studies implicating colonic polyamines in colon carcinogenesis induced by dietary arginine or dietary sources of the polyamines themselves.

Figure 1
Relationship between Wnt signalling, the APC tumour-suppressor gene and polyamine metabolism in colonic epithelium

Dietary arginine and colon carcinogenesis

Arginine is catabolized by arginase for production of ornithine, which serves as a substrate for polyamines. Arginine is also a substrate for NOS (nitric oxide synthase), resulting in NO production. These relationships are depicted in Figure 2. We have evaluated the role of dietary arginine and the NOS2 gene in intestinal and colon carcinogenesis in the ApcMin/+ mouse model. We chose a range of dietary arginine levels for our studies in mice that corresponded to human diets ranging from low to high in arginine amounts. We found that dietary arginine enhanced colon tumour incidence and grade in the ApcMin/+ model. Loss of NOS2 alleles blocked the arginine-dependent increases in colon tumorigenesis in this model [11]. Treatment of ApcMin/+ mice with DFMO (difluoromethylornithine) suppressed the arginine-dependent increase in both colon tumour burden and grade [12]. These data provide evidence that dietary arginine is a luminal risk factor for colon carcinogenesis in the ApcMin/+ mouse model, and that NOS2 and ODC mediate this risk. It is useful here to note that inhibition of ODC enzyme activity with the inhibitor DFMO had little effect on colon tumorigenesis in ApcMin/+ mice fed diets not supplemented with arginine [1,13]. Thus DFMO may affect colon tumorigenesis in this model only when colon tumorigenesis is induced, as in the case of supplemental arginine. Arginine increases not only the number of colonic tumours in these mice, but also the tumour grade as assessed by both size and morphological parameters. The major effect of DFMO is to reduce the grade of arginine-induced colon tumours. We speculate that arginine-induced colon tumorigenesis might represent a risk factor for human colon tumorigenesis, and that DFMO may exert its anti-colon carcinogenic effects on high grade adenomas. However, both these points remain to be established.

Figure 2
Metabolic pathways involving arginine and colon tumorigenesis

Dietary polyamines and colon carcinogenesis

Several studies have shown that intestinal and dietary polyamines can influence tumorigenesis at distant sites [14,15], and in some cases, minimize the effects of ODC inhibitors [16]. Dietary polyamines have been found to enhance intestinal and colonic tumorigenesis [17]. Recent studies from our group indicate that the primary effect of dietary putrescine is to increase tumour grade [18]. Our mouse studies used dietary putrescine levels (1% in the drinking water) that are equivalent to humans drinking 1–2 cups per day of grapefruit juice [19]. Attenuation of tumour growth by depletion of tissue polyamines may require inhibition of both polyamine synthesis, via ODC, and polyamine uptake. One group has already reported evidence supporting this hypothesis [20]. The relative importance of inhibiting apical versus basolateral polyamine transport, as depicted in Figure 1, is unknown.

Influence of dietary polyamines on responses to colon cancer preventive agents

The NSAID (non-steroidal anti-inflammatory drug) sulindac displays chemopreventive activity in patients with FAP [21]. Sulindac metabolites induce apoptosis in colon tumour cells, in part, by a polyamine-dependent mechanism which can be suppressed with exogenous putrescine [22]. To determine the relevance of this mechanism in animals, we treated ApcMin/+ mice, a model of human FAP, with sulindac alone or in combination with dietary putrescine (1% in the drinking water). Sulindac increased steady-state RNA levels and enzymatic activity of the polyamine catabolic enzyme SSAT (spermidine/spermine N1-acetyltransferase), and intestinal levels of monoacetylspermidine, spermidine and spermine, in the small intestine of mice [18]. Dietary putrescine increased intestinal putrescine contents while the combination of dietary putrescine and sulindac yielded the highest levels of intestinal putrescine. Sulindac reduced intestinal tumour number by nearly 90%. The effectiveness of sulindac to suppress intestinal carcinogenesis was partially abrogated by dietary putrescine. These data suggest that sulindac exerts at least some of its anti-carcinogenic effects in mice via a polyamine-dependent mechanism. While these results were reassuring, in that they supported our interpretation that sulindac was acting in part by a mechanism involving polyamines, they raise another concern. High concentrations of putrescine can be found in common diets. For example, mice consuming 1% putrescine in drinking water take in a similar amount of putrescine as a human consuming 1–2 cups of grapefruit juice per day [19]. Sulindac is prescribed for a number of clinical indications thought to involve inflammation, it may be advantageous to restrict dietary putrescine consumption in patients undergoing treatment with this NSAID. It is unknown whether this effect of putrescine is limited to sulindac or if dietary putrescine might adversely affect the efficacy of other NSAIDs. We have found that several NSAIDs, including sulindac, as discussed earlier, aspirin [23,24] and celecoxib [25] influence polyamine metabolism in part by cyclo-oxygenase-independent mechanisms inducing SSAT. If these NSAIDs act to suppress tissue polyamine contents, then sufficient dietary putrescine would be expected to reduce the efficacy of their actions related to polyamine-dependent processes. On the other hand, effects such as those mediated by cyclo-oxygenases may be unaffected. Alternatively, dietary polyamines could be affecting metabolism of NSAIDs. There is evidence that putrescine can decrease the activity of cytochrome P450 3A4 levels in a rat liver model [26]. This cytochrome has been implicated in the metabolism of certain NSAIDs under specific conditions [27].

Relevance of animal studies to humans

The dibasic amino acid arginine is a conditionally essential amino acid known to be involved in several important physiological functions, but its role in cancer is poorly understood [28]. In our mouse studies discussed above, we found that dietary arginine could enhance colon tumorigenesis in the ApcMin/+ mouse model of FAP. We fed our mice arginine concentrations ranging from 1 to 4 g of arginine per kg of body weight per day [11]. These concentrations correspond to the higher range of arginine consumed by humans eating a Western style diet [29], when corrected for the approx. 7.5-fold higher metabolic rate in mice, compared with humans [30]. Consequently, dietary arginine could be a risk factor for colon carcinogenesis in humans.

In order to test the potential significance of our mouse studies, which have suggested important roles for dietary arginine in colon carcinogenesis, we evaluated self-reported meat consumption (as a surrogate for arginine intake) in a group of patients from a gene-environment study [25]. We found that patients with a family history of colorectal cancer and reporting meat consumption in the highest quartile had a statistically significantly decreased overall survival and increased risk of death, compared with those in the lower quartiles [25]. These results suggest that overall meat consumption may have a significant role in human colon carcinogenesis. Since meat is the major source of dietary arginine, together with our animal studies, these findings suggest that dietary arginine may be involved in human colon carcinogenesis.

Our observations that dietary putrescine also enhanced colon tumorigenesis in ApcMin/+ mice, especially in terms of tumour grade, and that dietary putrescine can suppress the chemopreventive action of sulindac, may also be relevant to humans. Putrescine is found in high amounts in orange and grapefruit juice [19], and consequently can be consumed by humans in levels approaching those used in our mouse studies [18].

Approaches to limit dietary arginine and dietary polyamines may be useful strategies for colon cancer prevention. Arginine and polyamines derived from either dietary or intestinal luminal sources, such as enteric bacteria, may promote colon tumorigenesis in adult humans, while the polyamines may act to reduce the efficacy of colon cancer prevention strategies such as NSAID treatment. Others have already developed special diets low in polyamines for cancer patients [31]. In the future, our group will be prospectively assessing the roles of dietary arginine and putrescine contents in human cancer chemoprevention trials to determine the relevance of these factors in human colon cancer prevention and treatment.

Abbreviations used

APC
adenomatous polyposis coli
DFMO
difluoromethylornithine
FAP
familial adenomatous polyposis
NOS
nitric oxide synthase
NSAID
non-steroidal anti-inflammatory drug
ODC
ornithine decarboxylase
SSAT
spermidine/spermine N1-acetyltransferase.

References

1. Erdman SH, Ignatenko NA, Powell MB, Blohm-Mangone KA, Holubec H, Guillen-Rodriguez JM, Gerner EW. Carcinogenesis. 1999;20:1709–1713. [PubMed]
2. Fultz KE, Gerner EW. Mol. Carcinogen. 2002;34:10–18. [PubMed]
3. Behrens J. Biochem. Soc. Trans. 2005;33:672–675. [PubMed]
4. Babbar N, Gerner EW. Biochem. Soc. Trans. 2003;31:388–392. [PubMed]
5. Gerner EW, Meyskens FL., Jr Nat. Rev. Cancer. 2004;4:781–792. [PubMed]
6. Iwamoto M, Ahnen DJ, Franklin WA, Maltzman TH. Carcinogenesis. 2000;21:1935–1940. [PubMed]
7. Ignatenko NA, Holubec H, Besselsen DG, Blohm-Mangone KA, Padilla-Torres JL, Dexter E, Nagle RB, Moreno de Alboran I, Gullien RJ, Gerner EW. Cancer Biol, Ther. 2006;5:1658–1664. [PubMed]
8. Milovic V. Eur. J. Gastroenterol. Hepatol. 2001;13:1021–1025. [PubMed]
9. Milovic V, Turchanowa L, Stein J, Caspary WF. World J. Gastroenterol. 2001;7:193–197. [PubMed]
10. Brosnan JT. J. Nutr. 2003;133:2068S–2072S. [PubMed]
11. Yerushalmi HF, Besselsen DG, Ignatenko NA, Blohm-Mangone KA, Padilla-Torres JL, Stringer DE, Cui H, Holubec H, Payne CM, Gerner EW. Mol. Carcinogen. 2006;45:93–105. [PubMed]
12. Yerushalmi HF, Besselsen DG, Ignatenko NA, Blohm-Mangone K, Padilla Torres J, Stringer DE, Cui H, Holubec H, Payne CM, Gerner EW. Mol. Carcinogen. 2006;45:764–773. [PubMed]
13. Halberg RB, Katzung DS, Hoff PD, Moser AR, Cole CE, Lubet RA, Donehower LA, Jacoby RF, Dove WF. Proc. Natl. Acad. Sci. U.S.A. 2000;97:3461–3466. [PubMed]
14. Sarhan S, Knodgen B, Seiler N. Anticancer Res. 1989;9:215–223. [PubMed]
15. Sahan S, Knodgen B, Seiler N. Anticancer Res. 1992;12:457–466. [PubMed]
16. Hessels J, Kingma AW, Ferwerda H, Keij J, van den Berg GA, Muskiet FA. Int. J. Cancer. 1989;43:1155–1164. [PubMed]
17. Loser C, Eisel A, Harms D, Folsch UR. Gut. 1999;44:12–16. [PMC free article] [PubMed]
18. Ignatenko NA, Besselsen DE, Stringer DE, Blohm-Mangone K, Padilla-Torres J, Cui H, Gerner EW. Nutr. Cancer. 2006;56:172–181. [PMC free article] [PubMed]
19. Zoumas-Morse C, Rock CL, Quintana E, Neuhouser ML, Meyskens FL, Jr, Gerner EW. J. Am. Diet. Assoc. 2007 in the press. [PMC free article] [PubMed]
20. Belting M, Borsig L, Fuster MM, Brown JR, Persson L, Fransson LA, Esko JD. Proc. Natl. Acad. Sci. U.S.A. 2002;99:371–376. [PubMed]
21. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJ. N. Engl. J. Med. 1993;328:1313–1316. [PubMed]
22. Babbar N, Ignatenko NA, Casero RA, Jr, Gerner EW. J. Biol. Chem. 2003;278:47762–47775. [PubMed]
23. Martinez ME, O'Brien TG, Fultz KE, Babbar N, Yerushalmi H, Qu N, Guo Y, Boorman D, Einspahr J, Alberts DS, et al. Proc. Natl. Acad. Sci. U.S.A. 2003;100:7859–7864. [PubMed]
24. Babbar N, Gerner EW, Casero RA., Jr Biochem. J. 2006;394:317–324. [PubMed]
25. Zell JA, Yerushalmi HF, Ignatenko NA, Besselsen DE, Ziogas A, Gerner EW, Anton-Culver H. Int. J. Cancer. 2007;120:459–468. [PubMed]
26. Favre C, Monti JA, Scapini C, Pellegrino J, Carnovale CE, Carrillo MC. J. Hepatol. 1998;28:700–708. [PubMed]
27. Rodrigues AD. Drug Metab. Dispos. 2005;33:1567–1575. [PubMed]
28. Lind DS. J. Nutr. 2004;134:2837S–2841S. discussion 2853S. [PubMed]
29. Venho B, Voutilainen S, Valkonen VP, Virtanen J, Lakka TA, Rissanen TH, Ovaskainen ML, Laitinen M, Salonen JT. Am. J. Clin. Nutr. 2002;76:359–364. [PubMed]
30. Hawk CT, Leary SL, Morris TH. Formulary for Laboratory Animals. 3rd edn Blackwell Publishing; Ames: 2005.
31. Cipolla B, Guilli F, Moulinoux JP. Biochem. Soc. Trans. 2003;31:384–387. [PubMed]